Within the foregoing six studies, the primary aim was to prolong the efficacy of ketamine using an oral agent as continuation therapy. All six oral continuation trials were well tolerated without any significant safety concerns reported. Three trials had no significant reported dissociative effects 20, 26, 35; however, the remaining three trials 24, 33, 34 did report significant, although mild and transient dissociative effects. Ketamine treatments, as part of the Interventional Psychiatry Service at Yale Psychiatric Hospital, are given in an electroconvulsive therapy suite. After psychiatric consultation, signed informed consent (See Supplemental Information) and medical clearance (including basic lab work, urine toxicology, electrocardiogram, and history and physical examination), patients began intravenous infusions. As emphasized in the written consent form, patients understood that this treatment was not approved by the Food and Drug Administration and was given off-label for depression.
The IBM program aims to increase the desire for change by speaking about predisposing factors, explaining the most effective refusal skills, showing examples of effective desire control, and right behavior with relapsing sensation. Behavior change occurs by recognizing which behavior needs to be altered primarily with hard efforts and motivation83. On the other hand, EAU was presented by one lawyer, two MD psychiatrists, one infectious disease MD physician, and one PhD counselor/therapist.
Advancing knowledge of ketamine’s therapeutic window and risks will promote its safe clinical integration. The recent opioid crisis has sparked renewed interest in ketamine’s analgesic properties, necessitating the development of consistent guidelines to maximize its benefits while mitigating potential psychomimetic and cardiovascular effects86,87. An SDDK of 0.6 mg/kg has been identified as effective for pain relief without significant psychomimetic side effects. The latest safety protocols stress strict dosing and monitoring practices to reduce the risk of respiratory, cardiovascular, and neuropsychiatric complications, particularly as ketamine infusion therapy: techniques and efficacy ketamine is considered a viable alternative to opioids53,61. Integration of these techniques is critical during ketamine administration, particularly in emergency settings.
Ketamine and the Treatment of Mental Health Conditions
After thoroughly screening for appropriateness and relevance, 48 articles were included in this review. Due to its euphoric, dissociative, and hallucinogenic properties, ketamine has been abused as a recreational drug, which has led to rigid regulation of the pharmaceutical 3. Due to the dearth of evidence regarding the therapeutic value of ketamine for certain mental health conditions, including suicidal ideation, more research to address the major gaps is warranted.
Quality of the evidence
Ketamine is an N-methyl-D-aspartate receptor (NMDAR) antagonist that acts on the central nervous system (CNS) and acts on other CNS receptors 10. The water and lipid solubility of ketamine allows for good bioavailability and multiple administration routes, including the intravenous (I.V.), intramuscular, oral, rectal, subcutaneous (s.c.), epidural, and intranasal routes 10. Previous reports link ketamine with an intraocular pressure increase and nystagmus 12, as well as hypertension and supraventricular tachycardia in patients with hyperthyroidism or taking thyroxine 10,12. Additionally, evidence suggests that the inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by ketamine and its effect on the opioid receptors may also contribute to its overall anesthetic impact 13.
Ketamine therapy side effects
- Two patients were discharged on nonmedical reasons and one patient was dropped following switch to hypomanic episode.
- In October 2014, our institution began providing ketamine as an off-label therapy for patients not able to participate in research protocols on a case-by-case basis.
- Although ketamine shows promise in treating various diseases, its psychoactive side effects and abuse potential limit its widespread use26.
- Ketamine, originally developed as anesthesia, was first discovered to work similarly to antidepressants as early as 1975.
- Thus, the effects of early-life ketamine administration maybe age and sex-specific, and it is possible that adolescent administration of ketamine for the treatment of depression may lead to an increased risk of addiction later on in life 42.
While in 2015, this figure increased to 3 million (1.1%) for individuals aged 12 and older27. However, recent 2020 statistics show a decline in ketamine misuse, with 1.1 million Americans using it as a hallucinogen28. However, prolonged use can lead to cognitive impairments, including memory and concentration issues, as well as tolerance and physical or psychological dependence. These risks have led to ketamine being classified as a Schedule III controlled substance in the U.S.10.
Medical
Originally developed as an anesthetic, ketamine has shown remarkable efficacy in treating conditions such as depression, anxiety, PTSD, and chronic pain when administered in controlled, low doses. The therapy typically involves a series of intravenous infusions in a clinical setting under medical supervision. The ketamine infusion studies have provided evidence of a clinically meaningful (albeit transitory) analgesic benefit; something that is all too rare in the pharmacological management of CRPS.
Rodriguez says she understands what motivates the clinicians to prescribe the drug now to patients in dire straits — those who are suicidal or who have tried every possible medication and therapeutic option and continue to suffer each day. Ketamine was first synthesized in the early 1960s as a safer alternative to phencyclidine 8. Its use in contemporary anaesthesia is limited given the occurrence of a variety of side effects, most importantly the induction of a psychedelic state causing agitation, hallucinations and panic attacks (i.e. emergence and excitation symptoms).
Two patients were discharged on nonmedical reasons and one patient was dropped following switch to hypomanic episode. Data were analyzed using the IBM SPSS Statistics for Windows, version XX (IBM Corp., Armonk, NY, USA). Paired t-test was applied to see changes in various scales compared to baseline at 1 h and 2 weeks after last dose of ketamine and after 1 month of the last dose. In one study, 88% of the participants given a ketamine infusion in the emergency room had their suicidal ideation go away in just 90 minutes.
Data analysis was performed using Review Manager 5.4.1, focusing primarily on pain scores. Secondary outcomes, including quality of sleep, and side effects such as nausea, hallucinations, and sedation, were also examined. This study aims to conduct a contemporary meta-analysis to provide updated insights into the application of IV ketamine infusion therapy for persistent pain. By synthesizing findings from a diverse array of research studies conducted in recent years, this meta-analysis seeks to illuminate the current landscape surrounding the application of ketamine infusion therapy in addressing persistent pain conditions.
Patients relapsed (some symptoms returned) on an average of 19 days after, but some did not relapse for more than three months. A significant body of evidence has tested the attractive hypothesis that pre-emptive administration of ketamine might prevent the development of pain (both acute and chronic) by preventing the sensitization of neuronal circuits. Although positive findings were reported from animal studies, the data from human trials have not shown a clear pre-emptive benefit 23. However, the acute analgesic effects of ketamine can outlast the expected half-life of the drug, suggesting that there may indeed be some suppression of neural sensitization in pain circuits 24. Most recently, ketamine has attracted attention because it can produce an improvement in depressive symptoms in man after acute administration 18. These antidepressant actions are causing a stir in the field because of the rapid onset of therapeutic effect (unique amongst the currently available medications), which may enable its use as an acute treatment of severe depression.
- Ketamine is a noncompetitive, use-dependent NMDA channel blocker that could prevent the induction of synaptic potentiation.
- However, the acute analgesic effects of ketamine can outlast the expected half-life of the drug, suggesting that there may indeed be some suppression of neural sensitization in pain circuits 24.
- Learn about the benefits of animal-assisted therapy (AAT) and the difference between service animals, emotional support animals, and therapy animals.
- After the patient verbally confirmed an absence of any concerning symptoms, an additional 4 mL of 0.5% bupivacaine was slowly injected over 1 min for a total injection volume of 8 mL for a single-level block.
This review will cover safety considerations and risk mitigation strategies to minimize adverse effects and promote recovery. These strategies include selection criteria, monitoring requirements, dose adjustments, and measures to prevent misuse. In a retrospective study assessing peritraumatic use of ketamine in war-wounded soldiers, it was concluded that ketamine did not affect PTSD prevalence 47. Although ketamine neither decreases nor increases the chances of developing PTSD, it does have a potential use for maintenance treatment 48-50. Despite the suggestion of the Veterans Affairs guidelines to not use ketamine in PTSD due to the lack of current evidence in favor of its use, some patients with PTSD have received off-label treatment with ketamine 48,49. In 2020, a retrospective study analyzed internet posts on the Bluelight website, a public forum intended to provide a platform for people to discuss their drug use, and evaluated the self-reported use of ketamine in patients with PTSD 49.